Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EPS (Weighted Average and Diluted) (2021 - 2025)

Gyre Therapeutics (GYRE) has disclosed EPS (Weighted Average and Diluted) for 9 consecutive years, with $0.03 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 200.0% to $0.03 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.04, a 102.74% increase, with the full-year FY2024 number at $0.05, up 103.55% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.03 for Q3 2025 at Gyre Therapeutics, up from $0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.64 in Q2 2022 to a low of -$1.51 in Q4 2023.
  • A 5-year average of -$0.23 and a median of $0.01 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 345.86% in 2022, then crashed 98.78% in 2023.
  • Gyre Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.65 in 2021, then plummeted by 96.92% to -$1.28 in 2022, then dropped by 17.97% to -$1.51 in 2023, then skyrocketed by 100.66% to $0.01 in 2024, then skyrocketed by 200.0% to $0.03 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's EPS (Weighted Average and Diluted) are $0.03 (Q3 2025), $0.01 (Q2 2025), and $0.01 (Q3 2024).